Adaptin Bio Inc (APTN)

$6.27 0.00 (N/A)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 200
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 100%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Adaptin Bio, Inc., a biotechnology company, develops drug delivery technologies to deliver drugs and other compounds directly to target destinations within the body in the United States. It provides Brain Bispecific T-cell Engager platform, a bispecific antibody technology to target and treat intracerebral malignancies, such as gliomas. It develops APTN-101, a proprietary epidermal growth factor receptor variant III to eliminate malignant glioma tumors in a range of aggressive preclinical tumor...

Phone: 888 609 1498
Address:
3540 Toringdon Way, Suite 200 #250, Charlotte, United States
BioTuesdays
BioTuesdays Jul. 14 at 3:13 PM
$APTN is advancing a novel strategy to overcome one of the most persistent challenges in neuro-oncology—delivering effective therapies across the blood-brain barrier. By leveraging the natural trafficking ability of immune cells, the company’s proprietary bispecific T-cell engager platform is designed to transport therapeutic agents directly to intracerebral tumors. https://biotuesdays.com/2026/07/14/adaptin-bio-is-leveraging-immune-cell-hitchhiking-to-target-brain-tumors/
0 · Reply
Latest News on APTN
No data available.
BioTuesdays
BioTuesdays Jul. 14 at 3:13 PM
$APTN is advancing a novel strategy to overcome one of the most persistent challenges in neuro-oncology—delivering effective therapies across the blood-brain barrier. By leveraging the natural trafficking ability of immune cells, the company’s proprietary bispecific T-cell engager platform is designed to transport therapeutic agents directly to intracerebral tumors. https://biotuesdays.com/2026/07/14/adaptin-bio-is-leveraging-immune-cell-hitchhiking-to-target-brain-tumors/
0 · Reply